

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV 11-96)		ATTORNEY'S DOCKET NUMBER 17620-9277
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		
INTERNATIONAL APPLICATION NO. PCT/US98/02899	INTERNATIONAL FILING DATE 13 February 1998	PRIORITY DATE CLAIMED 13 February 1997
U.S. APPLICATION NO. (If known) 09/402636		
TITLE OF INVENTION TARGETED THERAPEUTIC DELIVERY OF VITAMIN D COMPOUNDS		
APPLICANT(S) FOR DO/EO/US Richard B. Mazess & Charles W. Bishop		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information: 		

U.S. APPLICATION NO. (if known, see 37 CFR 1.51)	INTERNATIONAL APPLICATION NO. PCT/US98/02899	ATTORNEY'S DOCKET NUMBER 17620/9277
09/402636		CALCULATIONS PTO USE ONLY
<input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 and International Search Report not prepared by the EPO or JPO International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT = <input type="text" value="\$ 760.00"/>		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="text" value="\$ 130.00"/>		
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	40 - 20 =	20
Independent claims	7 - 3 =	4
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$260.00
TOTAL OF ABOVE CALCULATIONS = <input type="text" value="\$ 1562.00"/>		
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). <input type="text" value="\$ 781.00"/>		
SUBTOTAL = <input type="text" value="\$ 781.00"/>		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). + <input type="text" value="\$ -0-"/>		
TOTAL NATIONAL FEE = <input type="text" value="\$ 781.00"/>		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + <input type="text" value="\$ -0-"/>		
TOTAL FEES ENCLOSED = <input type="text" value="\$ 781.00"/>		
Amount to be: <input type="checkbox"/> refunded <input type="checkbox"/> charged <input type="text" value="\$"/>		
a. <input checked="" type="checkbox"/> A check in the amount of <input type="text" value="\$ 781.00"/> to cover the above fees is enclosed.		
b. <input type="checkbox"/> Please charge my Deposit Account No. <input type="text"/> in the amount of <input type="text"/> to cover the above fees. A duplicate copy of this sheet is enclosed.		
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <input type="text" value="50-0842"/> A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending g status.		
SEND ALL CORRESPONDENCE TO: Teresa J. Welch Michael Best & Friedrich LLP One South Pinckney Street, Suite 700 P.O. Box 1806 Madison, WI 53701-1806 (608) 257-3501		
 SIGNATURE: <input type="text" value="Teresa J. Welch"/> NAME: <input type="text" value="Teresa J. Welch"/> 33,049 REGISTRATION NUMBER: <input type="text"/>		

PATENT

Docket No. 2833.29

Applicant or Patentee: Richard B. Mazess et al.

Serial or Patent No.: 60/038,364

Filed or Issued: February 13, 1997

FOR: TARGETED THERAPEUTIC DELIVERY OF VITAMIN D COMPOUNDS

**VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(B))
INDEPENDENT INVENTOR(S)**

As the below-named inventor, I hereby declare that I am qualified as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled: TARGETED THERAPEUTIC DELIVERY OF VITAMIN D COMPOUNDS described in:

the specification filed herewith
 Application Serial No. 60/038,364, filed February 13, 1997
 Patent No. , issued

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

no such person, concern, or organization
 persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27).

Full Name: Bone Care International, Inc.

Address: 313 West Beltline Highway, Madison, Wisconsin 53713
 Individual Small Business Concern Nonprofit Organization

Full Name: _____

Address: _____
 Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein are of my own knowledge, are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Richard B. Mazess

Name of Inventor




Signature of Inventor

4 April 1997

Date

Charles W. Bishop

Name of Inventor



Signature of Inventor

Apr. 14, 1997

Date

TARGETED THERAPEUTIC DELIVERY OF VITAMIN D COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the priority date, under
35 U.S.C. § 119, of United States Provisional Application Number
5 60/038,364, filed 13 February 1997.

**STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT**

Not applicable

BACKGROUND OF THE INVENTION

This invention relates generally to the targeted therapeutic delivery of vitamin D compounds and, in particular, delivery to bone and tumor tissue.

Too often the practicing clinician is faced with an irresolvable dilemma. To effectively achieve therapy against a disease, it becomes necessary to balance the devastation wrought by the illness against the noxious effects conferred by the drugs used to treat it. Although therapy should represent a complete tolerance to the dose regimen, in absolute terms it frequently delineates a compromise position, thereby effecting only an "acceptable" level of treatment.

In the absence of preventive measures to combat the onset of disease, the next ideal alternative is to design a drug that specifically recognizes the origin of the disorder and then corrects it. This so-called "magic bullet" or site-specific drug delivery concept is not a new concept. Such a concept is directed to linking the action of drugs to specific receptor-mediated events. These concepts still serve as a primary foundation for the continuing development of drugs and antibodies.

Chemical modification of a drug, in some cases enhances its target organ specificity. For example, brain-targeted delivery systems based on the dihydropyridine-pyridinium salt redox interconversion have been developed

for compounds such as estradiol and ethinylestradiol. Brewster et al., 31 *J. Med. Chem.* (1988) 244. Covalent coupling of some sugars to drugs can enhance their uptake by the liver. Ponpinom et al., in Receptor Mediated Targeting of Drugs, (Gregoriadis et al, eds.) NATO ASI series, Plenum Press, 5 New York, 1983, p. 53.

In most cases, however, a specific carrier is needed that is designed for transport and delivery of the drug to its target tissue. In such cases, the distribution characteristics of the drug itself are irrelevant, since the carrier characteristics determine whether the drug is delivered to the target cells. 10 However, once delivered to the target cells, it still will be necessary to consider the distribution of the drug at its intracellular effect site.

A number of particles have been proposed as drug carrier systems. Recent interest has focused on monoclonal antibodies and colloidal delivery systems such as liposomes and polymeric microspheres. See, e.g., Davis 15 et al. in Site-Specific Drug Delivery, (Tomlinson et al. eds.), John Wiley, New York, 1986, p.93.

Soluble molecules have also been proposed as drug carriers, including DNA, lectins, poly-L-lysine, virosomes, insulin, dextran, HCG, dipeptides and even cellular systems such as erythrocytes and fibroblasts. See, e.g., 20 Poznansky et al., 36 *Pharmacol. Rev.* (1984) 277. Still others have suggested and attempted to use lipoproteins as drug carriers, especially low-density lipoproteins. See, e.g., Counsell et al., 25 *J. Med. Chem.* (1982) 1115.

Obviously, the need for site-specific drug delivery is highest in 25 pathological conditions such as cancer and severe viral infections. Side effects of the drugs utilized in the treatment of neoplastic diseases often are quite severe. Other fast-growing tissues such as bone marrow and gastrointestinal border cells are affected by the antineoplastic drug, and therapy will often have to be stopped.

The need for site-specific drug delivery is also high in bone conditions, 30 particularly osteoporosis. With the recognition that osteoporosis occurs to some extent in all postmenopausal women, the site-specific delivery of bone

agents to the mineralized bone matrix has been proposed. Certain agents are known for their bone-seeking characteristics or bone affinity, and the linkage of such bone-seeking agents to enzymes, steroids, or hormones to provide a bone-specific drug delivery agent has been advanced. For example, it has been proposed to join a bone-seeking agent, such as tetracycline, to a carbonic anhydrase inhibitor through a bridging agent to provide compounds for the treatment of or prophylaxis of degenerative bone diseases. See, European Patent Application No. 201,057.

Further, it has been taught to link a hormone, e.g., calcitonin or insulin-like growth factor, to an amino methylene bisphosphonic acid. See, Japanese Patent Application No. 2104-593A. U.S. Patent Number 5,183,815 discloses that the linkage of a steroid to an alkyl bisphosphonic acid can exhibit a localized therapeutic effect on bone. European Patent Application No. 0 512 844 A1 discloses linkage of a bone growth factor, such as transforming growth factor-beta, to bone-targeting molecules such as tetracycline, calcitonin, bisphosphonates, polyaspartic acid, polyglutamic acid, aminophosphosugars, or estrogens to provide a local bone-augmenting formation agent.

Vitamin D has long been established as having an important biologic role in bone and mineral metabolism. It is well known that vitamin D plays a critical role in stimulating calcium absorption and regulating calcium metabolism. The discovery of active forms of vitamin D, (M.F. Holick et al., 68 *Proc. Natl. Acad. Sci. USA*, 803-804 (1971); G. Jones et al., 14 *Biochemistry*, 1250-1256 (1975) and active vitamin D analogs (M.F. Holick et al., *Science* 180, 190-191 (1973); H.Y. Lam et al., *Science* 186, 1038-1040 (1974)), caused much excitement and speculation about the usefulness of these vitamin D compounds in the treatment of bone depletive disorders.

Animal studies examining the effects of these active vitamin D compounds suggested that such agents would be useful in restoring calcium balance. Further, an early clinical study indicated that administration of 0.5 μ g/day of $1\alpha,25$ -dihydroxyvitamin D₃, the hormonally active form of

RECEIVED - DECEMBER 10 1998

vitamin D₃, to a group of postmenopausal women improved the intestinal calcium absorption as well as the calcium balance in the women. On this basis, U.S. Patent 4,225,596 ("596 Patent") described and claimed the use of 1 α ,25-dihydroxyvitamin D₃ for increasing calcium absorption and retention. Such use also was claimed in the same patent for 1,25-dihydroxyvitamin D₂, and 1 α -hydroxyvitamin D₂, which compounds, the patent teaches, are "eminently suitable and readily substitutable for the 1,25 dihydroxycholecalciferol [1 α ,25-dihydroxyvitamin D₃]."

The best indicator of the efficacy of vitamin D compounds in the prevention or treatment of depleting bone disorders, however, is bone itself rather than calcium absorption or calcium balance. More recent clinical data indicates that, at the dosage ranges taught in the '596 Patent, 1 α ,25-dihydroxy-vitamin D₃ has, at best, modest efficacy in preventing or restoring loss of bone mass or bone mineral content (S.M. Ott and C.H. Chesnut, *Ann. Int. Med.* 110:267-274 (1989); J.C. Gallagher et al., *Ann. Int. Med.* 113:649-655 (1990); J. Aloia et al., *Amer. J. Med.* 84:401-408 (1988)).

These clinical studies with 1 α ,25-dihydroxyvitamin D₃, and another conducted with 1 α -hydroxyvitamin D₃ (M. Shiraki et al., *Endocrinol. Japan* 32, 305-315 (1985)), indicate that the capacity of these two vitamin D compounds to restore lost bone mass or bone mineral content is dose-related. These studies also indicate, however, that at the dosage ranges required for either of the compounds to be truly effective, toxicity in the form of hypercalcemia and hypercalciuria becomes a major problem. Specifically, attempts to increase the amount of 1 α ,25-dihydroxyvitamin D₃ above 0.5 μ g/day have frequently resulted in toxicity. At dosage levels below 0.5 μ g/day, no effects are observed on bone mass or mineral content. (See G.F. Jensen et al., *Clin. Endocrinol.* 16, 515-524 (1982); C. Christiansen et al., *Eur. J. Clin. Invest.* 11, 305-309 (1981)). Two μ g/day of 1 α -hydroxyvitamin D₃ was found to have efficacy in increasing bone mass in patients exhibiting senile osteoporosis (O.H. Sorensen et al., *Clin. Endocrinol.* 7, 169S-175S (1977)). Data from clinical studies in Japan,

a population that has low calcium intake, indicate that efficacy is found with 1 α -hydroxyvitamin D₃ when administered at 1 μ g/day (M. Shiraki et al., *Endocrinol. Japan.* 32:305-315 (1985); H. Orimo et al., *Bone and Mineral* 3, 47-52 (1987)). At 2 μ g/day, however, toxicity with 1 α -hydroxyvitamin D₃ occurs in approximately 67 percent of the patients, and at 1 μ g/day, this percentage is approximately 20 percent.

More recently, other roles for vitamin D have come to light. Specific nuclear receptors for 1 α ,25-dihydroxyvitamin D₃ have been found in cells from diverse organs not involved in calcium homeostasis. For example, Miller et al., 52 *Cancer Res.* (1992) 515-520, have demonstrated biologically active, specific receptors for 1 α ,25-dihydroxyvitamin D₃ in the human prostatic carcinoma cell line, LNCaP.

More specifically, it has been reported that certain vitamin D compounds and analogs are potent inhibitors of malignant cell proliferation and inducers/stimulators of cell differentiation. For example, U.S. Patent No. 4,391,802 issued to Suda et al. discloses that 1 α -hydroxyvitamin D compounds, specifically 1 α ,25-dihydroxyvitamin D₃ and 1 α -hydroxyvitamin D₃, possess potent antileukemic activity by virtue of inducing the differentiation of malignant cells (specifically leukemia cells) to nonmalignant macrophages (monocytes), and are useful in the treatment of leukemia. In another example, Skowronski et al., 136 *Endocrinology* (1995) 20-26, have reported antiproliferative and differentiating actions of 1 α ,25-dihydroxyvitamin D₃ and other vitamin D₃ analogs on prostate cancer cell lines.

Previous proliferation studies, such as those cited above, focused exclusively on vitamin D₃ compounds. Even though such compounds may indeed be highly effective in differentiating malignant cells in culture, their practical use in differentiation therapy as anticancer agents is severely limited because of their equally high potency as agents affecting calcium metabolism. At the levels required *in vivo* for effective use as antileukemic agents, these same compounds can induce markedly elevated and potentially dangerous blood calcium levels, by virtue of their inherent calcemic activity.

That is, the clinical use of 1α ,25-dihydroxyvitamin D₃ and other vitamin D₃ analogs as anticancer agents is precluded, or severely limited, by the risk of hypercalcemia. This indicates a need for compounds with greater specific activity and selectivity of action, i.e., vitamin D compounds with 5 antiproliferative and differentiating effects but which have less calcemic activity than therapeutic amounts of the known compounds or analogs of vitamin D.

Virtually nothing in the art proposes materials or methods for the targeted delivery of vitamin D compounds to specific target tissue, e.g., 10 bone or malignancy sites, such as prostatic cancer cells.

BRIEF SUMMARY OF THE INVENTION

The present invention provides conjugates of vitamin D compounds or analogs and a targeting molecule, having an ability for site-specific delivery of the vitamin D. Specific conjugates include a bone-therapeutic conjugate and an anti-tumor conjugate. The present invention also provides pharmaceutical formulations of such a conjugate, and methods of site-specific delivery of a vitamin D moiety of the conjugate to a tissue of interest in a patient. The present invention provides surprisingly useful means for 15 delivery of vitamin D compounds, analogs or derivatives to tissues of interest (i.e., to target tissue).

The conjugates of the present invention comprises at least one vitamin D moiety associated with a target molecule moiety having an affinity for the target tissue. In one embodiment of the invention, the conjugate includes at least one vitamin D moiety associated with the target molecule 20 moiety via at least one connecting group, such as a bond between the vitamin D moiety and the target molecule moiety, a bifunctional connector, or other connectors such as a biotin-avidin linkage. In another embodiment, the conjugate includes a target molecule moiety having an affinity for the tissue of interest, associated with at least one vitamin D moiety and with a 25 second therapeutic agent other than vitamin D.

The pharmaceutical compositions of the present invention include a conjugate of at least one vitamin D moiety associated with at least one target molecule moiety, and a suitable pharmaceutically acceptable carrier.

In another embodiment, the present invention provides a method for site-specific delivery of vitamin D or an analog of vitamin D, a method which includes administering to a patient a therapeutically effective dose of a conjugate in a pharmaceutically acceptable carrier, wherein the conjugate has at least one vitamin D moiety associated with at least one target molecule via a connector, and wherein the target molecule has an affinity for a tissue of interest. The method is designed to effect site-specific delivery of the vitamin D moiety to the tissue of interest in the patient.

The conjugate, pharmaceutical composition and method of this invention allow for target-specific delivery of vitamin D to a specific tissue in a patient. By specifically targeting and delivering a vitamin D compound as part of the conjugates of this invention, one can effect delivery of the compound to the targeted tissue by administering relatively small amounts of the conjugate to a patient compared to delivery of the same amount of the compound by administration of the compound itself. By reducing the amount of vitamin D compound administered, the present invention significantly reduces the risk of hypercalcemia and other side-effects of administration of vitamin D compounds or analogs to patients using conventional means of administration.

Other advantages and a fuller appreciation of specific adaptations, compositional variations, and physical attributes will be gained upon an examination of the following detailed description of preferred embodiments, taken in conjunction with the figures of the drawing. It is expressly understood that the drawings herein are for the purpose of illustration and description only, and are not intended as a definition of the limits of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The preferred exemplary embodiment of the present invention will hereinafter be described in conjunction with the appended drawings, wherein like designations refer to like elements throughout, and in which:

5 Figure 1 illustrates a reaction scheme for the preparation of a conjugate of $1\alpha,24\text{-dihydroxyvitamin D}_2$ (" $1\alpha,24\text{-(OH)}_2\text{D}_2$ ") and aminoalkyl-1,1-bisphosphonate linked at C-24 of the vitamin D moiety;

10 Figures 2A and 2B illustrate a reaction scheme for the preparation of a conjugate of $1\alpha,24\text{-(OH)}_2\text{D}_2$ and aminoalkyl-1,1-bisphosphonate linked at C-1 of the vitamin D moiety;

15 Figure 3 illustrates a reaction scheme for the preparation of a conjugate of $1\alpha,24\text{-(OH)}_2\text{D}_2$ and aminoalkyl-1,1-bisphosphonate linked at C-3 of the vitamin D moiety;

20 Figure 4A and 4B illustrate a reaction scheme for the preparation of a conjugate of $1\alpha,25\text{-dihydroxyvitamin D}_3$ ($1\alpha,25\text{-(OH)}_2\text{D}_3$) and aminoalkyl-1,1-bisphosphonate linked at C-1 of the vitamin D moiety;

25 Figure 5 illustrates a reaction scheme for the preparation of a conjugate of $1\alpha,25\text{-(OH)}_2\text{D}_3$ and aminoalkyl-1,1-bisphosphonate linked at C-3 of the vitamin D moiety;

30 Figure 6 illustrates a reaction scheme for the preparation of a conjugate of $1\alpha,25\text{-(OH)}_2\text{D}_3$ and aminoalkyl-1,1-bisphosphonate linked at C-25 of the vitamin D moiety; and

Figure 7 is a schematic diagram for preparation of a conjugate of vitamin D and a monoclonal antibody, utilizing a biotin-avidin connector.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the use of vitamin D formulations in targeting applications. However, the present invention is most particularly adapted for use in site-specific delivery of vitamin D to bone and tumor cells. Accordingly, the present invention will now be described in detail with respect to such endeavors. However, those skilled in the art will appreciate

DRAFT - 35704-001

that such a description of the invention is meant to be exemplary only and should not be viewed as limiting the full scope thereof.

The present invention is characterized by an ability for site-specific targeting of vitamin D compounds using conjugates of vitamin D and a targeting molecule having affinity for a tissue of interest. For example, a conjugate of vitamin D and a bone affinity agent is designed to transport and deliver vitamin D to bone. These attributes are achieved through a novel combination of physical and chemical features.

In the following description of the invention, process steps are carried out at room temperature and atmospheric pressure, unless otherwise specified.

As used herein, the term "target molecule" or "targeting molecule" refers to a molecule that binds to or influences metabolism of the tissue of interest. For example, bone-targeting agents may include bone-seeking molecules such as tetracycline, calcitonin, bisphosphonates, chelators, phosphates, polyaspartic acid, polyglutamic acid, aminophosphosugars, peptides known to be associated with mineral phase of bone such as osteonectin, bone sialoprotein and osteopontin, protein with bone mineral binding domains, and the like. Bone-targeting molecules may also include molecules which themselves affect bone resorption and bone formation rates, such as bisphosphonates, estrogens and other steroids, such as dehydroepiandrosterone (DHEA). These bone-seeking molecules may also possess bone growth therapeutic properties and/or result in a synergistic or additive effect with the vitamin D compound on bone resorption or formation. Skin-seeking molecules include certain metal ion-amino acid chelates; prostate-seeking molecules include certain steroids such as DHEA. Tumor-seeking agents include certain antibodies.

As used herein, the terms "tissue of interest" or "target tissue" are meant to refer to a desired target or site in the body for treatment or for placement of a vitamin D compound or analog. The term "treat" or "treatment" is meant to refer to repair, prevention, alleviation, amelioration, prophylaxis of a diseased or defective tissue of interest as well as inhibition


DOCUMENT-00000000000000000000000000000000

-10-

of abnormal growth, such as hyperproliferation of cells, and promotion of cell differentiation.

As used herein, the term "therapeutic agent" refers to a material which has or exhibits healing powers when administered to or delivered to the tissue of interest. The term "bone-therapeutic agent" is used herein to refer to a specific type of therapeutic agent, one which ameliorates bone diseases or disorders when delivered or administered to bone. Examples of bone-therapeutic agents include vitamin D compounds, conjugated estrogens or their equivalents, antiestrogens, calcitonin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin, boron and other bone growth factors such as transforming growth factor beta, activin or bone morphogenic protein.

The conjugates in accordance with the present invention include at least one vitamin D compound, analog, component, or moiety (herein designated as "D") associated with at least one target molecule moiety (herein designated as "T") and include those represented by formula (I):




wherein n and m represent integers of 1 or greater; and * indicates that the target molecule moiety (T) is associated with the vitamin D compound, analog, component or moiety (D). It is understood that as used herein, the term "vitamin D" includes all compounds having the conventional vitamin D structure of A, C and D rings and C-17 side chain as well as previtamin D compounds which are the thermal isomers of their corresponding vitamin D forms, in which the basic structures may be substituted, unsubstituted or modified, e.g., 19-nor compounds. It is also understood that the vitamin D moiety maintains its biological effectiveness in the conjugate, e.g., its beneficial effect with respect to bone, or in the case of the previtamin D, isomerizes to its corresponding D form having the biological effectiveness.

As used herein, the terms "associated with" or "association" are meant to refer to attachment or linkage of one component of the conjugate (e.g., the vitamin D moiety) or vitamin D moiety and connector to another component of the conjugate, e.g., the target molecule or target molecule and


-11-

connector, via covalent bonding, hydrogen bonding, metallic bonding, van der Wall forces, ionic bonding, coulombic forces, hydrophobic or hydrophilic forces, adsorption or absorption, chelate type association, or any combination thereof. The terms "moiety" and "component" used in connection with vitamin D or D₃, or in connection with target molecule moiety or T, are meant to refer to vitamin D or target molecule in the conjugated forms disclosed herein, i.e., after association occurs. Association between the vitamin D analog and the target molecule may occur at any position on the vitamin D analog molecule depending on the functionality of the target molecule. For example, a bisphosphonate or amide may suitably link at positions on the vitamin D compound or vitamin D analog molecule having a hydroxyl group, such as at C-1, C-3, C-24, C-25.

Vitamin D compounds and analogs operable in the present invention are suitably represented by formula (II):




wherein R¹ is H or OH; Z represents a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C₁ - C₁₈ hydrocarbon group; Y is a =CH₂ group; and t is 0 or 1, such that when t is 0, the compound of formula (II) is a 19-nor compound. Preferably, Z is a side chain represented by formula (IIIA):



-12-

wherein m is O or 1; R⁵ is H or OH; R⁶ and R⁷ are independently H, OH, lower alkyl, lower fluoroalkyl, O-lower alkyl, O-lower acyl, O-aromatic alkyl, lower cycloalkyl or, taken together with the carbon to which they are bonded (i.e., C-25), form a C₃-C₈ cyclohydrocarbon ring; and Q 5 is -C = C-, -C ≡ C-, or , R³ R⁴, wherein n is 0 or an integer from (-C-)n

1 to 7, R³ is CH₃ or H, and R⁴ is H or OH. For example, Z includes a cholesterol or ergosterol side chain represented by formula (IIIB):



10 wherein R⁸ and R⁹ are each H or taken together form a double bond between C-22 and C-23, R³ is CH₃ or H; R⁴ and R⁵ are independently H or OH; and R⁶ and R⁷ are independently H, OH, lower alkyl, lower fluoroalkyl, O-lower alkyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl or taken together with the carbon to which they are bonded (i.e., C-25) form a C₃-C₈ cyclocarbon ring.

15 Also included as vitamin D compounds within the scope of the present invention are *previtamin D* compounds, preferably 1*α*-hydroxy*previtamin D* which may include the common cholesterol and ergosterol side chains that 20 may optionally be substituted, preferably hydroxysubstituted, e.g., at C-24 or C-25. *Previtamin D* compounds are the thermal isomers of the corresponding vitamin D compounds, e.g., 1*α*-hydroxy *previtamin D*₃ is the thermal isomer of 1*α*-hydroxy vitamin D₃, and exists in thermal equilibrium with same.

25 Preferred among the target molecules are those which when used as a component of the conjugate of formula (I) result in at least a portion of the conjugate, specifically the vitamin D component of the conjugate, being delivered to a desired target (e.g., a targeted cell, a targeted organ, a tumor, etc.). The preferred target molecules include chemical functionalities


-13-

exhibiting target specificity, hormones (e.g., biological response modifiers), and antibodies, preferably, monoclonal or polyclonal antibodies, or antibody fragments having the requisite target specificity. Included among the preferred target molecules exhibiting specific affinity for bone are bisphosphonates, tetracycline, polymalonates and dehydroepiandrosterone.

The conjugates of formula (I) are prepared under conditions (such as particular pH, temperature or salt concentrations) which are not detrimental to the particular conjugate components and in the presence of a suitable solvent when required. To control pH, a buffer or addition of a suitable acid or base is used. The reaction conditions are dependent on the type of association (*) to be formed between the vitamin D compound or analog (D) and the target molecule moiety (T) in order to produce the conjugate.


The molar ratio of T:D in the conjugates of formula (I) is preferably 1:1.

Also within the scope of the present invention are those conjugates in which D is associated with T via connector (herein designated as "G") between D and T; these preferred conjugates are represented by the formula (IV):



wherein each G' represents the same or different connecting group; each G'' represents the same or different connecting group; g and k each individually represent an integer of 1 or greater; f and h each individually represent an integer of 0 or greater; — indicates a bond in instances where a connecting group is present; n and m are as previously defined herein; and * indicates that the target molecule component is associated with the vitamin D component via connector G' or G'' or via both connectors, in instances when both are present. It is understood that D maintains its biological effectiveness in the conjugate or, when D is a previtamin D, isomers to its corresponding vitamin D form having biological effectiveness.

In those cases wherein f or h is zero (and g and k are 1), the conjugate of formula (IV) is simply represented by formula (V):




-14-

In such cases, G is suitably a bifunctional connector, e.g., polyglutamic acid or polyaspartic acid, or a linkage group formed by modification of D and/or T and with subsequent bond formation.

Suitable connecting groups for use in forming the conjugates of formula (IV) are those which link the vitamin D moiety to the target molecule moiety without significantly impairing the biological effectiveness of the vitamin D, and without significantly impairing the affinity of the target molecule component of the conjugate. The connectors form a link between the target molecule moiety and the vitamin D moiety of the conjugate, a link which must be of sufficient stability to remain intact, at least until the conjugate is delivered to the region proximate the target. Under some circumstances, the vitamin D delivered to the target region as part of the conjugate is more effective after at least one connector linking the target molecule moiety and the vitamin D moiety is cleaved. In such cases, at least one such connector is preferably cleaved once the conjugate is delivered proximate the target. In other words, by cleaving the connectors in such cases, one can avoid steric hindrance between the vitamin D and the target molecule moiety which exists in some of the conjugates of the present invention, wherein such steric hindrance reduces the effectiveness of the vitamin D of the conjugate.

In an illustrated embodiment, the conjugate of the present invention includes an agent effective in treating bone disorders, i.e., the conjugate includes a vitamin D moiety and a bone-seeking agent. Preferred among the agents having bone affinity are bisphosphonates ("BP") (also referred to as diphosphonates). For example, a specific bisphosphonate moiety which is suitably operable in the present invention is represented by formula (VI):




-15-

wherein R² is H or OH, Y is NH, O or NR⁸ wherein R⁸ is H or C₁-C₄ alkyl, and n is an integer from 1 to 4. A particularly preferred bone-therapeutic conjugate, wherein T is a BP, is represented by formula (VII):




5 wherein BP is suitably linked at, e.g., the C-1, C-3, C-17, C-24, or C-25 position of the D moiety.

Specific bone-therapeutic conjugates suitable for use in the present invention, wherein T is a bisphosphonate, include conjugates of formula (VIII):




10 wherein R¹ is H or OH; R² is H or OH; X is O or S; Y is NH, O or NR wherein R is H or C₁-C₄ alkyl; n is 1-4; and pharmaceutically acceptable salts thereof, i.e., the bisphosphonate is linked to the vitamin D moiety at C-17.

Also provided are conjugates of formula (IX):



wherein R¹ is H or OH; R² is H or OH; R³ is CH₃ or H; R⁴ is H or OH, X is O or S; Y is NH, O or NR wherein R is H or C₁-C₄ alkyl; n is an integer from 1 to 4; R⁸ and R⁹ are each H or taken together form a double bond between C-22 and C-23; and pharmaceutically acceptable salts thereof, i.e., the bisphosphonate is linked at the C-25 position of the vitamin D moiety.

Also provided are conjugates of formula (X):




wherein R¹ is H or OH; R² is H or OH; R³ is CH₃ or H; R⁴ is H or OH, X is O or S; Y is NH, O or NR wherein R is H or C₁-C₄ alkyl; R⁶ is H or OH; n is an

0092470 - 35320460

-17-


integer from 1 to 4; R⁸ and R⁹ are each H or taken together form a double bond between C-22 and C-23; and pharmaceutically acceptable salts thereof, i.e., the bisphosphonate is linked to the vitamin D moiety at C-3.

Also provided are conjugates of formula (XI):



5 wherein R² is H or OH; R³ is CH₃ or H; R⁴ is H or OH, X is O or S; Y is NH, O or NR wherein R is H or C₁-C₄ alkyl; R⁵ is H or OH, n is an integer from 1 to 4, R⁸ and R⁹ are each H or taken together form a double bond between C-22 and C-23; and pharmaceutically acceptable salts thereof, i.e., the bisphosphonate linkage is at C-1 of the vitamin D moiety.

10 It is noted that typically the linkage between the bisphosphonate moiety and the vitamin D moiety is through a hydroxyl on the vitamin D where the hydroxyl is converted to a



group and is linked to the amine or hydroxy group, i.e., Y, of the bisphosphonate to form a carbamate-type or carbonate-type linkage. X can be O or S. For example, a hydroxyl group may be contained in the vitamin D structure at C-1, C-3, C-24, C-25, and conjugation can be effected at any hydroxyl position but is suitably one of the above.

-18-

Synthesis of the conjugates of formula (I), wherein T is a bisphosphonate, is accomplished according to the schema presented in Figures 1-6. In general terms, the synthesis includes conversion of a hydroxyl in the vitamin D to a haloformate (e.g., a chloroformate) or 5 thioformate group with subsequent reaction with the appropriate amino or hydroxyl group of the bisphosphonate to form a carbamate, thiocarbamate, carbonate or thiocarbonate linkage. If R² is hydroxy or the vitamin D compound contains one or more hydroxyl groups in addition to the desired hydroxyl group, these can be protected by conventional hydroxy-protecting 10 groups, such as benzyl, silyloxy, etc., prior to the reaction that converts the desired hydroxyl to a haloformate or thioformate group.

Specifically, in the illustrated embodiment, the starting vitamin D compound or analog (when appropriate, hydroxyl protected) is reacted with phosgene to form a chloroformate, the chloroformate is reacted with an aminobutyl-1,1-bisphosphonate to form a carbamate linkage. Any protected 15 hydroxyls are then deprotected.

Figure 1 is an illustrative scheme for the synthesis of a conjugate of 1 α ,24-(OH)₂D₂-aminoalkyl and 1,1-bisphosphonate. As seen in Figure 1, the 1 α ,24-(OH)₂D₂ starting material is protected by silyloxy groups in the C-1 20 and C-3 positions. The protected D compound (1) is reacted with phosgene in toluene to form the chloroformate (2). The chloroformate (2) is reacted with tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (i.e., hydroxyl-protected) in dichloromethane, and the reaction mix is purified via flash chromatography to yield the protected conjugate (4). The protected 25 conjugate (4) is reacted with tetrahydroform (THF) and tetrabutylammonium fluoride (TBAF) to deprotect the C-1 and C-3 hydroxyls to yield the tetraisopropyl ester of the conjugate (5). The tetraisopropyl ester (5) is hydrolyzed with trimethyl silylboride to form the conjugate bisphosphonic acid structure (6). Compound (6) and 9-acetylantracene in methanol are 30 irradiated, filtered, concentrated and lyophilized to yield the conjugate (7).

The syntheses illustrated in Figures 2-6 are discussed in detail in the Examples section, below.

Also, preferred among the conjugates of formula (I) are those in which T is DHEA. The common steroidal structure of DHEA has a 17-keto group and a 1-hydroxy group. Either of these groups may suitably be linked to hydroxylated positions on the vitamin D, e.g., through ether or ester-type linkages. Reactions for such linkages are well known.

Also desirable among the conjugates of formula (I) are those wherein T is a metal ion, M. Metal ions are known to target many tissue sites, e.g., strontium ion to bone. The conjugates may take the form of direct complexes between a vitamin D moiety and the metal ion wherein the moiety has a negatively charged terminal group, e.g., one having one or more carboxyl groups at C-24, C-25, etc., generally D-X⁻. The conjugate may be represented by the formula (XII):



wherein X is a negatively charged group such as a carboxyl, -CO₂⁻, and M is a divalent metal ion.

Alternatively, the conjugate may be of the form of formula (V) wherein D and M are associated by a connector, e.g., an amino acid. For example, it has been disclosed that metal ion-amino acid chelates are capable of targeting tissue site delivery. See, e.g., U.S. Patent Numbers 4,863,898; 4,176,564; and 4,172,072, each of which is incorporated herein by reference. For example, magnesium-lysine chelates have been shown to target bone; and zinc and methionine have been shown to target skin. Such chelates are of the form



wherein M is the metal ion and AA is an amino acid residue, (e.g. lysine, arginine, etc.), and * indicates an association of the amino acid residue (AA) with the metal ion (M). In the conjugates of the present invention, the amino acid of the metal-amino acid chelate is linked to the vitamin D moiety


-20-

through the amide-type linkage shown above in the case of when T is bisphosphonate. The conjugates are represented by the formula (XIII):



wherein D is a vitamin D moiety having a group capable of forming a linkage

5 to an amino acid, e.g., a hydroxy group; (AA) is the amino acid residue, and M is a metal ion, preferably a divalent ion such as Sr^{2+} , Zn^{2+} , Mg^{2+} , Fe^{2+} , Cu^{2+} , Mn^{2+} , Ca^{2+} , Cu^{2+} , Co^{2+} , Cr^{2+} or Mo^{2+} . More specifically, conjugates are provided in the form represented by the formula (XIV):



wherein D, M, AA, and * are as defined above.

10 Also preferred among the conjugates of formula (I) are those wherein T is an antibody. Antibodies or antibody fragment which may be used in such preferred conjugates can be prepared by techniques well known in the art. An example of suitable antibodies are immunoglobins, such as IgG, IgA, IgD and IgE. High specificity monoclonal antibodies can be produced by hybridization techniques well known in the art. See, e.g., Kohler et al., 245
Nature (1975) 495-497; and 6 Eur. J. Immunol. (1976) 511-519, both of which are incorporated herein by reference. Such antibodies normally may have a highly specific reactivity. Polyclonal antibodies are also suitable for use as the target molecule component of the conjugate. However, when the
20 target molecule moiety is an antibody, it is most preferably a monoclonal antibody (Mab).

Selected monoclonal antibodies are highly specific for a single epitope, making monoclonal antibodies particularly useful as the targeting molecule components of the conjugates of this invention. Conjugates of vitamin D and monoclonal antibodies can be targeted to specific sites within a target region, such as specific vitamin D receptors on the surface of cancerous tissue or in bone tissue. Methods for isolating and producing monoclonal or polyclonal antibodies to specific antigens, such as antibodies to selected

target tissue or even to specific target proteins are known. See, e.g., Molecular Cloning, 2n ed., Sambrook et al., eds., Cold Spring Harbor Lab.

Press 1989, § 18.3 *et seq.* Polyclonal antibodies can also be utilized and can be produced more cheaply than monoclonal antibodies. But, polyclonal

5 antibodies inherently are less specific targeting molecules. Nonetheless, it is possible to produce large amounts of monoclonal antibodies suitable for use in the conjugates of the present invention by tissue culture (e.g., a hybridoma cell line).

Conjugates of the present invention produced using such antibody
10 targeting molecules can be directed against, e.g., cells, organs, tumors, differentiation and other cell membrane antigens, polynucleic acids such as DNA and RNA or any biologically active molecule. Antibodies to vitamin D receptors of target cells of interest may be suitable for use in the conjugates of this invention.

15 For those conjugates in accordance with the present invention, when T is a monoclonal antibody, the T*D association is suitably done via a connector "G", e.g., a biotin-avidin linkage represented by G' - G", using biotin-avidin methodologies known in the art. Such a conjugate based on a connector, e.g., vitamin D-biotin-avidin antibody, is suitably represented as
20




A schematic diagram for the coupling of antibodies to vitamin D compounds or analogs using, e.g., biotin-avidin conjugates, is given in Figure 7.

Referring to Figure 7, avidin possesses a high affinity for the coenzyme biotin. This is a strong, noncovalent interaction which has been
25 exploited for the conjugation of antibodies to various compounds. The biotin or avidin is suitably coupled to either the vitamin D compound or the antibody component. As such, a number of different schemes are possible for linking vitamin D compounds and antibodies. For example, biotin is suitably linked to the antibody to form a biotinylated antibody complex, while
30 the avidin is suitably linked to the vitamin D compound to form an avidin vitamin D complex. The two complexes are subsequently reacted to form

-22-

an antibody-biotin-avidin-vitamin D conjugate. A vitamin D-biotin-avidin-antibody conjugate is formed in a similar manner as shown in Figure 7.

It may be desirable to conjugate hormones or other agents (designated as "A") to the conjugates of formula (I), to form a bifunctional conjugate represented by formula (XV)



wherein A represents a therapeutic agent other than vitamin D and p is an integer of 1 or greater, D, T, m and n are as previously defined herein, with the proviso that D and A maintain their biological effectiveness, and * indicates that the target molecule moiety is associated with the vitamin D moiety and with the therapeutic agent other than vitamin D. For example, a bifunctional conjugate of formula (XV) is one that has the ability to deliver vitamin D to bone as well as another osteogenic agent such as an estrogen.

Thus, included within the scope of the present invention are conjugates of formula (XV) which are bone-therapeutic conjugates wherein A is a hormone or other agents which are known to ameliorate bone diseases or disorders. Such bone agents may include conjugated estrogens or their equivalents, antiestrogens, calcitonin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin, boron, DHEA and other bone growth factors such as transforming growth factor beta, activin or bone morphogenic protein.

Also provided in the present invention are conjugates of formula (XV) which are antiproliferative conjugates wherein A is a cytotoxic agent. Such agents include estromustene, phosphate, prednimustine, cisplatin, S-fluorouracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

Included within the scope of the present invention are all possible enantiomers of any conjugate of the invention which exhibits optical isomerism and all possible geometric isomers due to a cis-trans configuration at double bonds. Additionally, all pharmaceutically acceptable salts of compounds described herein, such as sodium, potassium, lithium, ammonium salts of the compounds, and the like.

The magnitude of a prophylactic or therapeutic dose of the conjugates in accordance with the present invention will vary with the nature or the severity of the condition to be treated and with the particular composition and its route of administration. In general, the daily dose range for use in bone diseases lies within the range of about 0.025 nmol/kg of body weight to about 2.5 nmol/kg. The daily dose for treatment of hyperproliferative diseases, such as cancers, is in the range of about 0.025 nmol/kg to about 5 nmol/kg of body weight.

The conjugates of formula (II) are useful as active compounds in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogs of active forms of vitamin D₃.

The pharmacologically active conjugates of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. Any suitable route of administration may be employed for providing an effective dosage of the conjugate. For example, oral, rectal, topical, parenteral, intravenous, intramuscular, subcutaneous, ocular, nasal, buccal, and the like may be employed.

Pharmaceutical compositions of the present invention include the conjugate of the present invention as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The compositions are those suitable for the various routes of administration described herein, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the active ingredient. They are conveniently presented in unit dosage form.

Suitable pharmaceutically acceptable carriers for use in the composition or method of the present invention include, but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., corn oil, cottonseed oil, peanut oil, olive oil, coconut oil), fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates

(e.g., lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.

The pharmaceutical preparations can be sterilized and, if desired, be
5 mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring and flavoring. Additionally, the conjugate of the present invention may be coated or shielded to prevent immunogenicity or reticuloendothelial (RES) response by, e.g., the liver. Agents which can be used for this
10 purpose include polyethylene glycol (PEG) and others known in the art.

In another aspect, the present invention is a method of site-specific delivery of a vitamin D moiety to a tissue of interest in a patient, comprising:
15 (1) providing a conjugate of a vitamin D moiety and at least one target molecule moiety in a pharmaceutically acceptable carrier; and
(2) administering a therapeutically effective dose of the conjugate of the present invention described herein. However, the conjugate is preferably delivered in one of the following forms, depending upon the specific method of administration.

For parenteral application, particularly suitable are injectable, sterile
20 solutions, preferably oily or aqueous solution, as well as suspensions, emulsions, or implants, including suppositories. Ampoules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. A syrup, elixir,
25 or the like can be used if a sweetened vehicle is desired. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit.

For rectal administration, conjugates are formed into a pharmaceutical composition containing a suppository base such as cacao oil or other triglycerides. To prolong storage life, the composition advantageously includes an antioxidant, such as ascorbic acid, butylated hydroxyanisole or hydroquinone.

DOCUMENT IDENTIFICATION

-25-

Suitable topical formulations include transdermal devices, aerosols, creams, ointments, lotions, dusting powders and the like.

Oral administration of the pharmaceutical compositions of the present invention is preferred. The daily dosage of the compounds according to this invention generally is about 0.025 to about 2.5 nmol/kg, preferably about 0.025 to about 1 nmol/kg. Generally, the conjugates of this invention are dispensed by unit dosage form in a pharmaceutically acceptable carrier. For treatment of hyperproliferative diseases such as cancers, the enteral dosage of the conjugates of formula (I), is about 1 mmol to about 100 nmol per unit dosage; for bone diseases, about 0.5 nmol to 50 nmol per unit dosage.

In addition, those skilled in the art will also appreciate that such dosages may be encapsulated in time release, e.g., sustained, delayed or directed release delivery systems such as a liposome delivery system, polysaccharides exhibiting a slow release mechanism, salistic or other polymer implants or microspheres, as well as those where the active ingredient is suitably protected with one or more differentially degradable coatings, e.g., by microencapsulation, enteric coating, multiple coatings, etc., and such means effect continual dosing of compositions contained therein. For example, an enteric coating is suitably one which is resistant to disintegration in gastric juice. It is also possible to freeze-dry the active ingredient and use the lyophilizate obtained, e.g., for the preparation of products for injection.

It will further be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. For example, the specific dose for a particular patient depends on age, sex, body weight, general state of health, on diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities

DRAFT - 02/20/2001

of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.

The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.

Example 1: Synthesis of 1 α -(OH)-24-aminoalkyl-1,1-bisphosphonate-D₂ conjugate (7)

Reference is made to the reaction scheme of Figure 1. A solution of the known alcohol (1) (1.0 g, 1.52 mmol) in toluene (5 mL) is added to 22 mL of a 12.5% solution of phosgene in toluene and the solution is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide the chloroformate (2).

Pyridine (0.18 mL, 2.2 mmol) is added to a solution of (2) (1.1 g, 1.53 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate 3 (see, Saari et al., U.S. Patent 5,183,815) (0.92 g, 2.2 mmol) in CH_2Cl_2 (12 mL), and the mixture is stirred at room temperature for three days. The reaction mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to yield compound (4).

A solution of compound (4) (0.80 g, 0.74 mmol) in tetrahydrofuran (THF) (10 mL) and tetrabutylammonium fluoride (TBAF) (2.2 mL of a 1.0 M THF solution, 2.2 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (30 mL) and extracted with CH₂Cl₂ (3 x 40 mL). The combined CH₂Cl₂ fractions are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to yield tetraisopropyl ester compound (5).

Trimethylsilylboron (0.39 mL, 2.92 mmol) is added to a solution of the tetraisopropyl ester compound (5) (0.5 g, 0.58 mmol) in CH_2Cl_2 (6 mL), and the mixture is stirred at room temperature for 24 hrs. under an inert

-27-

atmosphere. The reaction mixture is concentrated under reduced pressure and the residue is diluted with water (15 mL). The mixture is filtered and the filtrate lyophilized to provide compound (6).

A solution of compound (6) (250 mg, 0.36 mmol) and 5 9-acetylanthracene (21 mg) in methanol (93 mL) is placed in an ACE 500-mL photo reactor and the solution is purged with nitrogen for 15 min. The reaction mixture is cooled to 0°C and irradiated with a 400 W Hanovia lamp filtered through uranyl glass for 2 hrs. The reaction mixture is filtered, and the filtrate is concentrated under reduced pressure. The residue is diluted 10 with water (10 mL). The mixture is filtered and the filtrate lyophilized to provide the above-titled conjugate (7).

Example 2: Synthesis of 1-aminoalkyl-1,1-bisphosphonate-24-(OH)-D₂ (16)

Reference is made to the reaction scheme depicted in Figures 2A & 2B. To a 0°C solution of compound (1) (2.0 g, 3.04 mmol), and 15 N,N-diisopropylethylamine (0.78 g, 6.1 mmol) in CH₂Cl₂ (25 mL) is added chloromethyl methyl ether (0.29 g, 3.6 mmol). The resulting reaction mixture is stirred at 0°C for 1 hr., then at room temperature for 7 hrs, prior to dilution with water (30 mL). The separated aqueous phase is extracted with CH₂Cl₂ (3 x 25 mL), and the combined organic phases are dried over 20 anhydrous sodium sulfate, filtered, and the filtrate is concentrated *in vacuo*. The residue is purified by flash chromatography over silica gel to provide compound (8).

A solution of compound (8) (1.99 g, 2.84 mmol) in THF (38 mL) and 25 TBAF (8.4 mL of a 1.0 M THF) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (100 mL), and extracted with CH₂Cl₂ (3 x 100 mL). The combined CH₂Cl₂ phases are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to yield the diol compound (9).

To a solution of diol (9) (1.25 g, 2.64 mmol), N, N-dimethylformamide (20 mL), and imidazole (0.54 g, 7.93 mmol) is added *tert*-butyldimethylsilyl

-28-

chloride (0.40 g, 2.64 mmol). The reaction mixture is stirred at room temperature for 6 hrs., prior to dilution with water (60 mL) and extraction with CH_2Cl_2 (3 x 70 mL). The combined organic phases are washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, to provide two products separately. They are identified in Figure 2A as alcohol (10) and alcohol (11).

As illustrated at the top of Figure 2B, a solution of alcohol (10) (0.5 g, 0.85 mmol) in toluene (2.5 mL) is added to 12.3 mL of a 12.5% solution of 10 phosgene in toluene and the solution is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide chloroformate (12).

Pyridine (0.09 mL, 1.1 mmol) is added to a solution of chloroformate 15 (12) (0.5 g, 0.77 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (3) (0.46 g, 1.1 mmol) in CH_2Cl_2 (6 mL) and the mixture is stirred at room temperature for three days. The reaction mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to yield compound (13).

20 A solution of compound (13) (0.50 g, 0.49 mmol) in THF (7 mL) and TBAF (0.74 mL of a 1.0 M THF solution, 0.74 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (20 mL) and extracted with CH_2Cl_2 (3 x 30 mL). The combined CH_2Cl_2 fractions are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated 25 under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to provide compound (14).

Trimethylsilyl bromide (0.26 mL, 1.96 mmol) is added to a solution of 30 tetraisopropyl ester (14) (0.35 g, 0.39 mmol) in CH_2Cl_2 (4 mL) and the mixture is stirred at room temperature for 24 hrs. under an inert atmosphere. The reaction mixture is concentrated under reduced pressure and the residue

DOCUMENT - 00000000000000000000000000000000

is diluted with water (15 mL) and methanol (3 mL) and is stirred for 8 hrs. The mixture is filtered and the filtrate lyophilized to provide compound (15).

A solution of compound (15) (0.21 g, 0.31 mmol) and 9-acetylanthracene (18 mg) in methanol (80 mL) is placed in an ACE 500-mL photo reactor, and the solution is purged with nitrogen for 15 min. The reaction mixture is cooled to 0°C and is irradiated with a 400 W Hanovia lamp filtered through uranyl glass for 2 hrs. The reaction mixture is filtered, and the filtrate concentrated under reduced pressure. The residue is diluted with water (10 mL). The mixture is filtered and the filtrate lyophilized to provide the above-titled conjugate (16).

Example 3: Synthesis of 1 α ,24-(OH)₂-3-aminoalkyl-1,1-bisphosphonate-D₂ (21)

Reference is made to Figure 3. A solution of alcohol (11) (0.5 g, 0.85 mmol) in toluene (2.5 mL) is added to 12.3 mL of a 12.5% solution of phosgene in toluene and the solution is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide chloroformate (17).

Pyridine (0.081 mL, 1 mmol) is added to a solution of (17) (0.45 g, 0.69 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (0.41 g, 1 mmol) in CH₂Cl₂ (5 mL), and the mixture is stirred at room temperature for three days. The reaction mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to provide compound (18).

A solution of compound (18) (0.47 g, 0.46 mmol) in THF (6.5 mL) and TBAF (0.7 mL of a 1.0 M THF solution, 0.7 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (20 mL) and extracted with CH₂Cl₂ (3 x 30 mL). The combined CH₂Cl₂ fractions are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as the eluent, to yield compound (19).

-30-

Trimethylsilyl bromide (0.23 mL, 1.74 mmol) is added to a solution of tetraisopropyl ester (19) (0.31 g, 0.34 mmol) in CH₂Cl₂ (4 mL) and the mixture is stirred at room temperature for 24 hrs under an inert atmosphere. The reaction mixture is concentrated under reduced pressure, and the residue is diluted with water (15 mL) and methanol (3 mL), and stirred for 8 hrs. The mixture is filtered, and the filtrate is lyophilized to provide compound (20).

A solution of compound (20) (0.21 g, 0.31 mmol) and 9-acetylanthracene (18 mg) in methanol (80 mL) is placed in an ACE 500-mL photo reactor, and the solution is purged with nitrogen for 15 min. The reaction mixture is cooled to 0°C and irradiated with a 400-W Hanovia lamp filtered through uranyl glass for 2 hrs. The reaction mixture is filtered, and the filtrate is concentrated under reduced pressure. The residue is diluted with water (10 mL). The mixture is filtered, and the filtrate is lyophilized to provide the above-titled conjugate (21).

Example 4: Synthesis of 1 α -aminoalkyl-1,1-bisphosphonate-25-(OH)-D₃ (32)

Reference is made to the reaction scheme depicted in Figures 4A and 4B. A solution of the known ketone (22) (3.1 g, 11.1 mmol) (see, Baggioini et al., 51 J. Org. Chem. (1986), 3098-3108), incorporated herein by reference, 3,4-dihydro-2H-pyran (1.52 mL, 16.7 mmol), and pyridinium p-toluenesulfonate (0.1 g, 0.4 mmol) are dissolved in CH₂Cl₂ (50 mL), and are stirred at room temperature for 24 hrs. The reaction mixture is washed with water (30 mL), and the organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel to yield ketone compound (23).

A solution of the known phosphine oxide (24) (1.35 g, 2.32 mmol) in 35 mL of anhydrous THF is cooled to -78°C and treated with *m*-butyllithium (1.45 mL of a 1.6 M solution in hexane) dropwise. The anion solution is stirred for 5 min. at -78°C prior to the addition of ketone (23) (0.57 g,

-31-

1.56 mmol) dissolved in anhydrous THF (10 mL) during 10-15 min. The reaction mixture is stirred for 2 hrs at -78°C then diluted with 2 N sodium potassium tartrate (6 mL) and 2 N potassium bicarbonate (6 mL). The solution is warmed to room temperature and extracted with ethyl acetate (4 x 25 mL). The combined organic fractions are washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing ethyl acetate/hexane as eluent, to provide compound (25).

A solution of compound (25) (0.95 g, 1.3 mmol) in THF (17 mL) and TBAF (3.9 mL of a 1.0 M THF solution, 3.9 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (50 mL) and extracted with CH₂Cl₂ (3 x 60 mL). The combined CH₂Cl₂ fractions are dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to provide diol compound (26).

To a solution of the diol compound (26) (0.55 g, 1.1 mmol), N,N-dimethylformamide (8 mL), and imidazole (0.255 g, 3.3 mmol) is added *tert*-butyldimethylsilyl chloride (0.166 g, 1.1 mmol). The reaction mixture is stirred at room temperature for 6 hrs., prior to dilution with water (30 mL) and extraction with CH₂Cl₂ (3 x 40 mL). The combined organic phases are washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, to provide two separate products. They are identified, at the bottom of Figure 4A, as alcohol (27) and alcohol (28).

A solution of alcohol (27) (0.25 g, 0.41 mmol) in toluene (3 mL) is added to 6 mL of a 12.5% solution of phosgene in toluene, and the reaction mixture is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide chloroformate (29), as shown at the top of Figure 4B.

-32-

Pyridine (0.047 mL, 0.57 mmol) is added to a solution of (29) (0.27 g, 0.4 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (0.24 g, 0.57 mmol) in CH_2Cl_2 (4 mL) and the mixture is stirred at room temperature for three days. The reaction mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to provide compound (30).

A solution of compound (30) (0.36 g, 0.35 mmol) in THF (5 mL) and TBAF (0.52 mL of a 1.0 M THF solution, 0.52 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (15 mL) and extracted with CH_2Cl_2 (3 x 25 mL). The combined CH_2Cl_2 fractions are dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to provide compound (31).

Trimethylsilyl bromide (0.20 mL, 1.54 mmol) is added to a solution of tetraisopropyl ester (31) (0.28 g, 0.30 mmol) in CH_2Cl_2 (4 mL), and the mixture is stirred at room temperature for 24 hrs. under an inert atmosphere. The reaction mixture is concentrated under reduced pressure and the residue diluted with water (15 mL) and methanol (3 mL) and stirred for 0.5 hr. The mixture is filtered, and the filtrate is lyophilized to provide the above-titled conjugate (32).

Example 5: Synthesis of $1\alpha,25-(\text{OH})_2$ -3-aminoalkyl-1,1 bisphosphonate-D₃ (36)

Reference is made to Figure 5. A solution of alcohol (28) (0.26 g, 0.43 mmol) in toluene (3 mL) is added to 6.2 mL of a 12.5% solution of phosgene in toluene and the reaction is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide chloroformate (33).

Pyridine (0.049 mL, 0.59 mmol) is added to a solution of chloroformate (33) (0.28 g, 0.42 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (0.25 g, 0.59 mmol) in CH_2Cl_2 (5 mL), and the mixture is stirred at room temperature for three days. The reaction mixture is

-33-

concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to yield compound (34).

5 A solution of compound (34) (0.37 g, 0.36 mmol) in THF (5 mL) and TBAF (0.54 mL of a 1.0 M THF solution, 0.54 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (15 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined CH₂Cl₂ fractions are dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue is purified by flash chromatography
10 over silica gel, utilizing methanol/chloroform as eluent, to yield tetraisopropyl ester (35).

Trimethylsilyl bromide (0.21 mL, 1.60 mmol) is added to a solution of the tetraisopropyl ester (35) (0.29 g, 0.31 mmol) in CH₂Cl₂ (5 mL), and the mixture is stirred at room temperature for 24 hrs under an inert atmosphere.
15 The reaction mixture is concentrated under reduced pressure, and the residue is diluted with water (15 mL) and methanol (3 mL) and stirred for 0.5 hr. The mixture is filtered, and the filtrate is lyophilized to provide the above-titled conjugate (36).

20 **Example 6:** Synthesis of 1 α -(OH)-25-aminoalkyl-1,1-bisphosphonate-D₃ (41)

Reference is made to Figure 6. To a solution of ether (25) (1.31 g, 1.8 mmol) in methanol (10 mL) and water (2 mL) is added pyridinium *p*-toluenesulfonate hydrate (0.034 g, 0.18 mmol). The reaction mixture is stirred at room temperature for 1 hr, diluted with water (20 mL) and extracted with CH₂Cl₂ (3 x 30 mL). The combined organic phases are dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to provide alcohol (37).

30 A solution of alcohol (37) (1.09 g, 1.7 mmol) in toluene (9 mL) is added to 25 mL of a 12.5% solution of phosgene in toluene, and the

-34-

reaction is stirred at room temperature for 20 hrs. The reaction mixture is concentrated under reduced pressure to provide chloroformate (38).

Pyridine (0.19 mL, 2.32 mmol) is added to a solution of chloroformate (38) (1.17 g, 1.65 mmol) and tetraisopropyl 4-aminobutyl-1,1-bisphosphonate (0.98 g, 2.32 mmol) in CH_2Cl_2 (20 mL), and the mixture is stirred at room temperature for three days. The reaction mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to yield alcohol (39).

A solution of alcohol (39) (1.61 g, 1.5 mmol) in THF (20 mL) and TBAF (4.5 mL of a 1.0 M THF solution, 4.5 mmol) is stirred at room temperature for 24 hrs. The reaction mixture is diluted with water (60 mL) and extracted with CH_2Cl_2 (3 x 60 mL). The combined CH_2Cl_2 phases are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography over silica gel, utilizing methanol/chloroform as eluent, to provide tetraisopropyl ester compound (40).

Trimethylsilyl bromide (0.75 mL, 5.68 mmol) is added to a solution of the tetraisopropyl ester compound (40) (0.93 g, 1.1 mmol) in CH_2Cl_2 (20 mL), and the mixture is stirred at room temperature for 24 hrs under an inert atmosphere. The reaction mixture is concentrated under reduced pressure and the residue is diluted with water (30 mL). The mixture is filtered and the filtrate is lyophilized to provide the above-titled compound (41).

In summary, the present invention provides vitamin D conjugates useful in targeting applications. The conjugates include a vitamin D moiety and a targeting molecule moiety having affinity for a tissue of interest. The conjugates are characterized by an ability for site-specific targeting of vitamin D compounds, e.g., a conjugate of vitamin D and a bone affinity agent is designed to transport and deliver vitamin D to bone tissue.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various

-35-

modifications, including variations, additions, and omissions, that may be made in what has been described.

-36-

CLAIMS

We claim:

1. A conjugate comprising at least one vitamin D moiety associated with a target molecule moiety having an affinity for a tissue of interest.
2. The conjugate of claim 1, wherein the molar ratio of the at least one vitamin D moiety to the at least one target molecule moiety is 1:1.
3. The conjugate of claim 1, wherein the vitamin D moiety is associated with the target molecule moiety via a connecting group.
- 10 4. The conjugate of claim 3, wherein the connecting group is a linkage group formed by modification of the vitamin D moiety and the target molecule moiety to form a bond therebetween.
5. The conjugate of claim 3, wherein the connecting group is a bifunctional connector.
- 15 6. The conjugate of claim 3, wherein the vitamin D moiety is associated with the target molecule moiety via the connecting group and at least one additional connecting group.
7. The conjugate of claim 1, wherein the target molecule moiety is a bisphosphonate moiety.
- 20 8. The conjugate of claim 1, wherein the target molecule moiety is a dehydroepiandrosterone moiety.

-37-

9. The conjugate of claim 7, wherein said bisphosphonate is linked to said vitamin D moiety at a position on the vitamin D moiety which is C-1, C-3, C-24 or C-25.

10. The conjugate of claim 1, wherein the target molecule moiety
5 is a metal ion.

11. The conjugate of claim 5, wherein the bifunctional connector is an amino acid chelated to the target molecule moiety and linked to the vitamin D moiety via an amide linkage.

12. The conjugate of claim 10, wherein the metal ion is a divalent metal ion selected from the group consisting of Sr^{2+} , Zn^{2+} , Mg^{2+} , Fe^2 , Cu^{2+} ,
10 Mn^{2+} , Ca^{2+} , Cu^{2+} , Co^{2+} , Cr^{2+} or Mo^{2+} .

13. The conjugate of claim 1, wherein the target molecule moiety is an antibody.

14. The conjugate of claim 13, wherein the antibody target
15 molecule moiety is associated with the vitamin D moiety via a biotin-avidin linkage, wherein the biotin is linked to the antibody and the avidin is linked to the vitamin D moiety.

15. The conjugate of claim 13, wherein the target molecule moiety is a monoclonal antibody.

20 16. The conjugate of claim 13, wherein the target molecule moiety is a polyclonal antibody.

17. The conjugate of claim 1, further comprising at least one therapeutic agent other than a vitamin D moiety conjugated therewith.

-38-

18. The conjugate of claim 17, wherein the therapeutic agent is a bone-therapeutic agent selected from the group consisting of conjugated estrogens or their equivalents, antiestrogens, calcitonin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin, boron, dehydroepiandrosterone, transforming bone growth factor beta, activin, and bone morphogenic protein.

19. The conjugate of claim 17, wherein the therapeutic agent is a cytotoxic agent selected from the group consisting of estromustene phosphate, prednimustine, cisplatin, S-fluorouracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

20. A pharmaceutical composition comprising:
a conjugate which includes at least one vitamin D moiety associated with at least one target molecule moiety having an affinity for a tissue of interest, and
15 a suitable pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, further comprising a differentially degradable coating encapsulating the conjugate for time release delivery of the conjugate.

22. The pharmaceutical composition of claim 21, wherein said coating is an enteric coating.

23. A method of site-specific delivery of a vitamin D moiety to a tissue of interest in a patient, comprising the steps of:

a. providing a conjugate which includes a vitamin D moiety in a pharmaceutically acceptable carrier, the conjugate having at least one vitamin D moiety associated with at least one target molecule moiety, the target molecule moiety having an affinity for the tissue of interest, and
25

PCT/US98/02899 - 38 -

-39-

b. administering a therapeutically effective dose of the conjugate to the patient.

24. The method of claim 23, wherein the conjugate is administered orally to a patient having a bone disease, at 0.5 nmol to 50 nmol per unit dosage.

5 25. The method of claim 23, wherein the conjugate is administered orally to a patient for the treatment of hyperproliferative diseases, at about 1 nmol to about 100 nmol per unit dosage.

10 26. The method of claim 23, wherein the conjugate is delivered to a tissue of interest after being administered to the patient.

27. The method of claim 26, wherein the target molecule moiety is cleaved after the conjugate is delivered to the tissue of interest, thereby enhancing the effectiveness of the vitamin D moiety of the conjugate.

15 28. A conjugate of formula (I)



wherein each D represents a vitamin D moiety; each T represents a target molecule moiety; n and m represent integers of 1 or greater; and * indicates that the target molecule moiety is associated with the vitamin D moiety.

20 29. An antiproliferative composition comprising the conjugate of claim 28, wherein T is an agent having an ability of seeking a vitamin D receptor of a cancerous cell.


30. The conjugate of claim 28 wherein T is a monoclonal, a polyclonal antibody or fragment thereof, a metal ion, a bone-seeking agent or a tumor-seeking agent.

DOCUMENT-OPENSOURCE

-40-

31. The conjugate of claim 30, wherein said bone-seeking agent is a bisphosphonate, a tetracycline, a polymalonate or dehydroepiandrosterone.


32. A conjugate of formula (IV)



5 wherein each G' represents a connecting group; each G'' represents the same or different connecting group as G'; each D represents a vitamin D moiety; each T represents a target molecule moiety; g, k, n and m represent integers of 1 or greater; and f and h represent integers of 0 or greater; - indicates a bond in instances where a connecting group is present; and * indicates that
10 each D is associated with each T via connector G' or G'' or via connector G' and G'' when both connectors are present.

33. The conjugate of claim 32 wherein G' is biotin; G'' is avidin and wherein * represents a biotin-avidin linkage.

34. The conjugate of formula (XV):



15 wherein each D represents a vitamin D moiety; each T represents a target molecule moiety; each A represents a therapeutic agent other than vitamin D; m, n and p represent integers of 1 or greater; and * indicates that the target molecule moiety is associated with the vitamin D moiety and with the
20 therapeutic agent other than vitamin D.

35. The conjugate of claim 34, wherein A is a cytotoxic agent or a bone therapeutic agent.

36. The conjugate of claim 35, wherein T is a bone-seeking agent.

37. A method of treating bone diseases in a human subject,
25 comprising administering to the subject a therapeutically effective amount of the conjugate of claim 36.

DOCUMENT-SEGMENTED

-41-

38. The conjugate of claim 34, wherein T is a bone-seeking agent and A is a bone-seeking agent.

39. A method of treating bone diseases in a human subject, comprising administering to the subject a therapeutically effective amount
5 of the conjugate of claim 38.

40. An antiproliferative composition comprising the conjugate of claim 34 wherein T is an agent having an ability of seeking a vitamin D receptor of a cancerous cell and A is a cytotoxic agent.

DRAFTING ATTACHED




FIG. 1

2/9




FIG. 2A

3 / 9





FIG. 2B

4 / 9






FIG. 4A

6/9



1, 25 - (OH)₂ D₃

FIG. 4B

7 / 9



1, 25 - (OH)₂ D₃

FIG. 5

8 / 9




FIG. 6

1, 25 - (OH)₂ D₃




FIG. 7

**DECLARATION FOR
UTILITY OR DESIGN
PATENT APPLICATION**

Declaration Submitted with Initial Filing
 Declaration Submitted after Initial Filing

First Named Inventor:

COMPLETE IF KNOWN

Application Number: 08/602,636
Filing Date: 13 February 1997
Group Art Unit:
Examiner Name:

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the sole joint inventor or the subject matter which is claimed and for which a patent is sought on the invention described.

TAKEN FROM THE PRACTICE DELIVERY OF VITAMIN D COMPOUNDS

The specification of which:

is attached hereto

was filed as United States Application Number 08/602,636.

I hereby swear that I have reviewed and understood the contents of the above-identified specification, including the claims, as recorded by my typewriter specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim benefit under 35 U.S.C. Title 35, United States Code § 111(a)(1) or § 365(d)(1) of any foreign application(s) for patent or inventor's certificate, or § 365(e) of any PCT international application which designated at least one country other than the United States of America, noted above and have also designated below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

First Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES NO
			<input type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Title 35, United States Code § 111(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)
60/138,361	13 February 1997

DECLARATION—Utility or Design Patent Application

I hereby claim the benefit under Title 35, United States Code 6 12a or any United States application(s), or 365(e) of any PCT international application(s), filed by me, the United States of America, listed below and similar to the subject matter of one of the claims of this application is not disclosed in the prior United States or PCT international applications in my name, prior and by the first paragraphs of Title 35, United States Code § 112, I acknowledge the date to earliest information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which becomes available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Patent Patent Number (if applicable)
10/115086/2000		February 13, 1998	

As a named inventor, I hereby, declare the following (including attachments) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number
Teressa J. Weisz	31,549
Michael Best & Friedrich LLP	28,011
One South Plazency Street, Suite 700	29,961
P.O. Box 1805	32,926
Madison, WI 53701-1800	41,814
United States of America	41,654
Telephone: (608) 257-3501	71,577
Fax: (608) 257-3225	21,306

Direct all correspondence to:

Teressa J. Weisz
Michael Best & Friedrich LLP
One South Plazency Street, Suite 700
P.O. Box 1805
Madison, WI 53701-1800
United States of America
Telephone: (608) 257-3501
Fax: (608) 257-3225

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that —willful false statements and the like in this application are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that each witness takes statement may jeopardize the validity of the application or any patent issued thereon.

Value of Gains from Income:	<input type="checkbox"/> A portion of the fee for this application			
For whom (First and middle (if any))	Family Name or Surname			
Karen R. Signature	Married			
Residence (City)	Address	State	Zip Code	Date
Post Office Address	3524 Blackhawk Drive	WI	53703	12/25/2000
Phone Number	(608) 257-3501			
City	Madison	State	WI	Zip Code

DECLARATION				Additional Inventor(s) Supplemental Sheet Page 1			
Name of Additional Solar Inventor: Given Name (first and middle if any)				<input type="checkbox"/> A petition has been filed for this unsigned Inventor Family Name or Surname			
Charles W.				Bishop			
Inventor's Signature	<i>X/Melissa Bishop</i>			Date	April 26, 00		
Residence (City)	Madison	State	WI	Country	US	Citizenship	US
Post Office Address	5 LaPoint Terrace						
Post Office Address							
City	Madison	State	WI	Zip Code	53710	Country	US

**DECLARATION FOR
UTILITY OR DESIGN
PATENT APPLICATION**

First Named Inventor:
COMPLETE IF KNOWN	
Application Number:	09/402,636
Filing Date:
Group Art Unit:
Examiner Name:

Declaration Submitted with Initial Filing
 Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am sole and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TARGETED THERAPEUTIC DELIVERY OF VITAMIN D COMPOUNDS

the specification of which

is attached hereto
 was filed as United States Application Number 09/402,636.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as contained by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations § 1.50.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(c) of any PCT international application which designated at least one country other than the United States of America, listed below and have also designated below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

First Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YY/YY)	Priority Not Claimed	Certified Copy Attached? YES NO

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YY/YY)
60/038,361	13 February 1997

DECLARATION—Utility or Design Patent Application

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
	PCT/US98/12899	February 13, 1998	

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number
Teressa J. Welch	31,048
Grady J. Friedrich	20,199
Linda Blale Meler	39,769
Paul E. Donovan	39,902
Jill A. Fahrlander	42,518
Karen B. King	41,859
David R. Price	31,537
David S. Smith	27,505

Direct all correspondence to:

Teressa J. Welch
Michael Best & Friedrich LLP
One South Pinckney Street, Suite 700
P.O. Box 1806
Madison, WI 53701-1806
United States of America
Telephone: (608) 257-3501
Fax: (608) 283-2275

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:	<input type="checkbox"/> A position has been filed for this unsigned Inventor							
Given Name (first and middle if any)		Family Name or Surname						
Richard B.		Mazers						
Inventor's Signature			Date					
Residence (City)	Madison	State	WI	Country	US	Citizenship	US	
Post Office Address	1534 Blackhawk Drive							
Post Office Address	City	Madison	State	WI	Zip Code	53705	Country	US

DECLARATION				Additional Inventor(s) Supplementary Sheet Page 1			
Name of Additional Joint Inventor: Given Name (first and middle if any)				<input type="checkbox"/> A power has been filed for this unsigned inventor Family Name or Surname			
Charles W.				Bishop			
Inventor's Signature				Date			
Residence (City)	Madison	State	WI	Country	US	Citizenship	US
Post Office Address	41 Lapoint Terrace						
Post Office Address							
City	Madison	State	WI	Zip Code	53710	Country	US

005247-00023-00000